Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoxia: targeting the tumour.

Robert George Boyle1, Stuart Travers

  • 1Sentinel Oncology Ltd., Cambridge, UK. bob.boyle@sentineloncology.com

Anti-Cancer Agents in Medicinal Chemistry
|July 18, 2006
PubMed
Summary

Tumour hypoxia, a common characteristic of solid tumours, promotes cancer aggressiveness and treatment resistance. Targeting this low-oxygen environment with novel bioreductive agents offers a promising strategy for developing new anti-cancer drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-activity studies on prolactin-releasing peptide (PrRP). Analogues of PrRP-(19-31)-peptide.

Journal of peptide science : an official publication of the European Peptide Societyยท2005
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Solid tumours frequently exhibit hypoxic (low oxygen) regions due to inadequate vascularization.
  • Tumour hypoxia is linked to radioresistance, chemoresistance, p53 mutations, and metastasis.
  • Hypoxia promotes an aggressive oncogenic phenotype, making it a critical target for cancer therapy.

Purpose of the Study:

  • To review current molecules and strategies for targeting tumour hypoxia.
  • To highlight the significance of hypoxia as a therapeutic target in solid tumours.

Main Methods:

  • Exploration of various chemical classes as bioreductive agents.
  • Focus on agents designed to selectively target hypoxic tumour regions.
  • Mention of tirapazamine as an advanced clinical candidate.

Main Results:

  • Hypoxia is a universal feature of solid tumours, driving key oncogenic processes.
  • Bioreductive agents, including N-oxides, quinones, and nitro-aromatics, are being investigated.
  • Tirapazamine is in Phase III clinical trials, demonstrating progress in hypoxia-targeted therapy.

Conclusions:

  • Targeting tumour hypoxia is a crucial strategy for overcoming treatment resistance and improving cancer outcomes.
  • The development of novel hypoxia-activated prodrugs and tumour-targeting agents is essential.
  • Further research into bioreductive agents holds significant promise for effective cancer drug discovery.

Related Experiment Videos